Radar · Life Sciences Tech in United States
Best Life Sciences Tech Companies in United States
The 2222 best Life Sciences Tech companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Verily.
By Rohit KhannaTrends & Stories
2222companies tracked
$41.1Bdisclosed funding
23unicorns
941have raised
Tracking the best Life Sciences Tech companies in the United States by disclosed equity funding and recent momentum, this directory covers 2,222 ventures and $41.1B in total capital raised. That's not a quiet corner of tech. Twenty-three unicorns have emerged from this pool, and the median app install growth across health and life sciences platforms is running at roughly +43% year-over-year. So the digital layer is catching up fast to the lab layer. Verily leads our rankings at $2.5B raised, with XtalPi close behind at $785M and Earendil at $787M rounding out the top tier. Investors like NIH, HHS, Y Combinator, and Lux Capital are the ones writing the early checks, which tells you something about how this sector straddles public-mission funding and pure venture appetite.
The themes shaping the next funding cycle are specific: device-biologic combinations, drug repurposing via AI, wearable biotech, and pharma's broader digital strategy. I'd watch the drug-repurposing AI thread especially hard right now, given how quickly that use case is attracting capital from traditional pharma and pure-play funds alike. Companies like Iambic Therapeutics ($206M) and Harbinger Health ($140M) show you don't need Verily-scale raises to move the conversation. If you're mapping this sector for partnership or investment, the signal is clear: the infrastructure is being built out fast, and the funding momentum reflects it.
Sources & further reading
- Latest News ATEC2026 Launches as the "Turing Test" for Embodied AI, Challenging
- Boeing's troubled capsule won't carry astronauts on next space station flight
- NASA’s Waste Management System Fails After Artemis II Launch, Sparking Conversat
FLIAR INTELLIGENCE · LIFE SCIENCES TECH × UNITED STATES
Our analysis of 50 Life Sciences Tech companies
$9.6b in tracked funding; 89% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
89%cloud-native stacks
2025funding peak (by rounds)
8unicorns
2018median founding year
936kcombined LinkedIn audience
56%of audience held by top 3
9companies hiring publicly (12 mo)
Ranked: Best Life Sciences Tech companies in United States
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Verily 🦄 A data platform and technology company purpose-built to power AI-enabled precision health 84News top 13%Funding top 14%Talent top 22%Growth top 25% All 12 signals ▾Newstop 13% Fundingtop 14% Talenttop 22% Growthtop 25% Moattop 26% Techtop 30% Markettop 31% Producttop 32% Customerstop 34% Partnerstop 41% Innovationtop 42% Globaltop 48% News: 7 BI events in 12 mo (of 67 tracked, 9 types) · +600% YoY Funding: Raised $2.5B across 5 rounds · 5 rounds over 9 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 84/100 | $2.5B | 3 mo ago | Series D | 1,564 | Andrew Conrad Co-Founder | 7 signals ▲600% Funding · New product · Layoffs | — | — |
| 2 | Earendil Provider of AI-driven technology platforms that enable the discovery and development of protein therapeutics 45Funding top 12%AI top 35%Talent top 38%Patents top 46% All 8 signals ▾Fundingtop 12% AItop 35% Talenttop 38% Patentstop 46% Innovationtop 50% Globaltop 50% Techbottom 36% Marketbottom 25% Funding: Raised $787M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: ai-driven, deep learning rank vs industry peers · Fliar Intelligence Index 45/100 | $787M | 2 mo ago | Series D | — | Zhenping Zhu Co-Founder & Co-CEO | — | 6 patents Therapeutic antibodies, especially bispecific and anti‑TL1A biologics for immune modulation | — |
| 3 | XtalPi 🦄 AI-based drug research and development company 64Funding top 18%AI top 26%Talent top 28%Patents top 31% All 13 signals ▾Fundingtop 18% AItop 26% Talenttop 28% Patentstop 31% Moattop 31% Innovationtop 34% Producttop 35% Newstop 38% Techtop 39% Growthtop 47% Globaltop 50% Marketbottom 43% Fin. healthbottom 32% Funding: Raised $785M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) AI: Classified as an AI company · Product described with: ai-based, machine learning rank vs industry peers · Fliar Intelligence Index 64/100 | $785M | 9 mo ago | Public | 27 | — | 4 signals Earnings | 14 patents Small-molecule STING agonists and PI3Kβ inhibitors for immuno‑oncology therapeutics | 1 partnership |
| 4 | Eikon 🦄 Protein tracking and measuring tool for drug discovery 60Funding top 14%News top 28%Moat top 28%Market top 38% All 10 signals ▾Fundingtop 14% Newstop 28% Moattop 28% Markettop 38% Growthtop 40% Techtop 43% Talenttop 44% Globalbottom 42% Patentsbottom 38% Innovationbottom 36% Funding: Raised $668M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) News: 8 BI events in 12 mo (of 23 tracked, 7 types) · +14% YoY rank vs industry peers · Fliar Intelligence Index 60/100 | $668M | 16 mo ago | Public | 331 | Robert Tjian Co-Founder | 8 signals IPO · Leadership · Earnings | 9 patents Automated vehicle intrusion barriers for rapid security deployment | — |
| 5 | Generate Biomedicines 🦄 Developer of a platform for generating novel protein-based therapeutic modalities 78AI top 18%Funding top 23%News top 24%Innovation top 25% All 12 signals ▾AItop 18% Fundingtop 23% Newstop 24% Innovationtop 25% Growthtop 25% Patentstop 25% Moattop 25% Talenttop 28% Markettop 45% Techbottom 43% Globalbottom 42% Fin. healthbottom 39% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $643M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $643M | 17 mo ago | Public | 75 | Gevorg Grigoryan Co-Founder & CTO | 6 signals IPO | 36 patents Patents concentrated in chemistry & materials | — |
| 6 | Enveda 🦄 AI-based platform to decipher the chemistry of nature and develop new medicines 72Funding top 12%Moat top 32%Growth top 35%Market top 44% All 8 signals ▾Fundingtop 12% Moattop 32% Growthtop 35% Markettop 44% AItop 45% Talentbottom 49% Globalbottom 48% Techbottom 46% Funding: Raised $505M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Moat: Unicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 72/100 | $505M | 9 mo ago | Series D | — | Viswa Colluru Founder & CEO | — | — | — |
| 7 | In Silico AI-enabled bioinformatics platform for drug discovery and biomarker development 82Funding top 15%Product top 19%AI top 20%News top 26% All 12 signals ▾Fundingtop 15% Producttop 19% AItop 20% Newstop 26% Partnerstop 26% Talenttop 28% Moattop 31% Innovationtop 35% Growthtop 35% Markettop 43% Techtop 46% Globalbottom 39% Funding: Raised $400M across 11 rounds · 11 rounds over 12 yrs (0.9/yr) Product: 3 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 82/100 | $400M | 17 mo ago | Public | 300 | Alex Zhavoronkov Co-Founder & Co-CEO | 9 signals ▲50% IPO · Contracts · Funding | — | — |
| 8 | Innovaccer 🦄 Developer of healthcare data platforms and artificial intelligence agent software 93Funding top 23%Tech top 25%AI top 25%Moat top 25% All 13 signals ▾Fundingtop 23% Techtop 25% AItop 25% Moattop 25% Markettop 26% Fin. healthtop 28% Talenttop 28% Innovationtop 29% Patentstop 32% Growthtop 33% Producttop 38% Globaltop 42% Newsbottom 24% Funding: Raised $379M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) Tech: 43 technologies across 6/8 capability areas · Cloud: Amazon S3, Amazon Ses rank vs industry peers · Fliar Intelligence Index 93/100 | $379M | 17 mo ago | Series F | 1,003 1,003 → 1,712 (+71%) | Abhinav Shashank Co-Founder & CEO | — | 30 patents Integrating and analyzing de‑identified healthcare data across clouds for clinical decision support | 1 partnership |
| 9 | Evidation Real-world health data insights for better healthcare decisions and research 72Funding top 20%Customers top 27%Tech top 31%Moat top 31% All 10 signals ▾Fundingtop 20% Customerstop 27% Techtop 31% Moattop 31% Producttop 36% Talenttop 38% Growthtop 41% Markettop 43% Globalbottom 37% Newsbottom 22% Funding: Raised $259M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) Customers: App rating 4.2★ (20,400 reviews) · Review volume +3% in 6 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $259M | 15 mo ago | Series E | 196 196 → 101 (-48%) | Christine Lemke Co-founder | — | — | — |
| 10 | Chai Discovery 🦄 Developer of artificial intelligence models for de novo molecular design 72Funding top 14%Talent top 28%AI top 30%Moat top 32% All 7 signals ▾Fundingtop 14% Talenttop 28% AItop 30% Moattop 32% Markettop 48% Globalbottom 48% Techbottom 42% Funding: Raised $230M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $230M | 6 mo ago | Series B | — | Joshua Meier Co-Founder | — | — | 1 partnership |
| 11 | Neuron23 AI-based drug discovery model for researchers 80Growth top 13%Funding top 18%Patents top 21%Moat top 21% All 10 signals ▾Growthtop 13% Fundingtop 18% Patentstop 21% Moattop 21% Innovationtop 23% AItop 45% Talentbottom 49% Globalbottom 40% Marketbottom 38% Newsbottom 18% Growth: Headcount 12 → 29 (+142%) across vintages · Fresh capital in last 24 mo Funding: Raised $214M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $214M | 11 mo ago | Series D | 29 29 → 28 (-3%) | Adam Knight Founder & CBO | — | 49 patents LRRK2 kinase inhibitor therapeutics and biomarkers for Parkinson's disease treatment | 1 partnership |
| 12 | Iambic Therapeutics Provider of AI-driven drug discovery platform for the treatment of cancer 60Funding top 15%AI top 26%Moat top 31%Talent top 38% All 9 signals ▾Fundingtop 15% AItop 26% Moattop 31% Talenttop 38% Growthtop 45% Marketbottom 43% Newsbottom 43% Techbottom 40% Globalbottom 39% Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) AI: Classified as an AI company · Product described with: ai driven, ai-driven rank vs industry peers · Fliar Intelligence Index 60/100 | $206M | 2 mo ago | Series C | 50 | Fred Manby Co-Founder & CTO | — | — | — |
| 13 | BrightInsight Provider of digital health solutions for clinical trials 57Funding top 18%Moat top 31%Growth top 35%Market top 50% All 8 signals ▾Fundingtop 18% Moattop 31% Growthtop 35% Markettop 50% Techbottom 49% Talentbottom 49% Newsbottom 43% Globalbottom 37% Funding: Raised $166M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 57/100 | $166M | 4 mo ago | Series C | 165 165 → 145 (-12%) | Frederik Smits Co-founder & Managing Director | — | — | — |
| 14 | Harbinger Health AI-based cancer detection tool for providers 55Funding top 18%News top 36%Moat top 42%AI top 45% All 8 signals ▾Fundingtop 18% Newstop 36% Moattop 42% AItop 45% Talenttop 49% Techbottom 48% Marketbottom 43% Globalbottom 38% Funding: Raised $140M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) News: 2 BI events in 12 mo (of 13 tracked, 3 types) · Top themes: Leadership rank vs industry peers · Fliar Intelligence Index 55/100 | $140M | 2 mo ago | Series B | 60 | Stephen Hahn CEO | — | — | 2 launchs |
| 15 | Diagonal Therapeutics Developer of antibody therapeutics for the treatment of rare diseases 40Funding top 19%Moat top 42%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 19% Moattop 42% Talentbottom 49% Marketbottom 40% Globalbottom 38% Funding: Raised $128M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Editorial + unicorn rating 5/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $128M | 5 mo ago | Series B | — | Alexey Lugovskoy CEO | — | — | — |
| 16 | Flywheel Cloud based data research platform 80Funding top 14%AI top 20%Product top 21%Moat top 31% All 10 signals ▾Fundingtop 14% AItop 20% Producttop 21% Moattop 31% Innovationtop 32% Techtop 33% Growthtop 35% Talenttop 38% Marketbottom 49% Globalbottom 39% Funding: Raised $110M across 10 rounds · 10 rounds over 8 yrs (1.2/yr) AI: Classified as an AI company rank vs industry peers · Fliar Intelligence Index 80/100 | $110M | 5 mo ago | Series D | 160 | Gunnar Schaefer Co-Founder | — | — | 1 partnership |
| 17 | Stipple Bio Provider of a platform that utilizes epitope-level resolution to unlock cellular profiling and target… 21Funding top 20%Talent top 38%Global bottom 48%Tech bottom 25% All 5 signals ▾Fundingtop 20% Talenttop 38% Globalbottom 48% Techbottom 25% Marketbottom 19% Funding: Raised $109M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $109M | 2 mo ago | Series A | 2 | Aaron Ring Co-Founder | — | — | 1 partnership |
| 18 | Atavistik Developer of allosteric therapeutics for precision oncology and rare diseases 50Funding top 19%Talent top 28%Moat top 31%Market bottom 42% All 6 signals ▾Fundingtop 19% Talenttop 28% Moattop 31% Marketbottom 42% Globalbottom 36% Newsbottom 33% Funding: Raised $100M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 3 mo ago | Series B | 33 | Ralph DeBerardinis Co-Founder | — | — | — |
| 19 | TetraScience Provider of a cloud-based data platform for life science industry 40Funding top 21%Growth top 26%Moat top 35%Tech top 50% All 9 signals ▾Fundingtop 21% Growthtop 26% Moattop 35% Techtop 50% Newsbottom 47% Globalbottom 39% Marketbottom 38% Patentsbottom 25% Innovationbottom 22% Funding: Raised $99.2M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) Growth: Headcount 13 → 30 (+131%) across vintages · Web rank 5,000,000 → 10,000,000 YoY rank vs industry peers · Fliar Intelligence Index 40/100 | $99M | 4 mo ago | Series B | 30 | — | — | 4 patents Real-time monitoring and feedback control systems for industrial tools and equipment | 1 job opening |
| 20 | Excelsior Sciences Developer of chemistry for automated small molecule discovery and manufacturing 72Funding top 21%Talent top 38%AI top 45%Global bottom 48% All 4 signals ▾Fundingtop 21% Talenttop 38% AItop 45% Globalbottom 48% Funding: Raised $95.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $95M | 6 mo ago | Series A | — | Michael Foley Co-Founder and Chief Executive Officer | — | — | — |
| 21 | Proxima Developer of a platform for programmable protein interaction-based drug discovery 42Funding top 24%Talent top 38%AI top 45%Tech bottom 45% All 6 signals ▾Fundingtop 24% Talenttop 38% AItop 45% Techbottom 45% Globalbottom 33% Marketbottom 31% Funding: Raised $86.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $86M | 5 mo ago | Seed | — | Luca Naef Co-Founder & CTO | — | — | — |
| 22 | AcuityMD Platform offering CRM software to the medical industry 53Funding top 18%News top 25%Talent top 28%Growth top 35% All 10 signals ▾Fundingtop 18% Newstop 25% Talenttop 28% Growthtop 35% Producttop 36% Moattop 39% Techtop 48% Marketbottom 42% Innovationbottom 37% Globalbottom 34% Funding: Raised $83.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) News: 4 BI events in 12 mo (of 11 tracked, 3 types) · Top themes: Funding, New product rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 1 mo ago | Series C | 48 | Michael Monovoukas Co-Founder & CEO | 4 signals Funding · New product | — | — |
| 23 | NTxBio Provider of bio informatics platform to develops biologics and therapeutics 45Funding top 22%Product top 30%Moat top 35%Talent top 38% All 10 signals ▾Fundingtop 22% Producttop 30% Moattop 35% Talenttop 38% Techtop 44% Growthtop 45% Patentstop 50% Innovationbottom 44% Globalbottom 35% Marketbottom 34% Funding: Raised $70.6M across 9 rounds · 9 rounds over 8 yrs (1.1/yr) Product: 7 distinct product lines · Company stage: Series B rank vs industry peers · Fliar Intelligence Index 45/100 | $71M | 6 mo ago | Series B | 32 | Alexander Koglin Co-Founder | — | 14 patents Patents concentrated in chemistry & materials | 1 launch |
| 24 | Tandem AI AI-based drug discovery tool for researchers 62Funding top 27%Moat top 32%Patents top 33%Talent top 38% All 10 signals ▾Fundingtop 27% Moattop 32% Patentstop 33% Talenttop 38% Innovationtop 41% Newstop 44% AItop 45% Marketbottom 49% Techbottom 46% Globalbottom 37% Funding: Raised $60.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 34 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $60M | 7 mo ago | Series A | 200 | Jeff He Co-Founder & CEO | — | 34 patents Optimized photovoltaic modules with parameter matching and UV filtering for solar power systems | 1 job opening · 1 launch |
| 25 | NewLimit 🦄 Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension 62Funding top 22%Talent top 28%Growth top 35%AI top 45% All 9 signals ▾Fundingtop 22% Talenttop 28% Growthtop 35% AItop 45% Techtop 46% Moattop 47% Marketbottom 36% Globalbottom 36% Newsbottom 18% Funding: Raised $60.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 62/100 | $60M | 7 mo ago | Series B | 8 | Jacob Kimmel Co-Founder | — | — | 4 job openings |
| 26 | Aureka Biotechnologies Biotech company digitizing therapeutic discovery to manage human health 55Funding top 20%AI top 35%Talent top 38%Market bottom 37% All 5 signals ▾Fundingtop 20% AItop 35% Talenttop 38% Marketbottom 37% Globalbottom 36% Funding: Raised $58.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) AI: Product described with: ai-based, artificial intelligence rank vs industry peers · Fliar Intelligence Index 55/100 | $58M | 1 mo ago | Series A | — | Weian Zhao Co-Founder & CEO | — | — | — |
| 27 | Cartography Biosciences Provider of a platform to discover immunotherapeutics 24Funding top 23%Moat top 31%News top 39%Talent bottom 49% All 6 signals ▾Fundingtop 23% Moattop 31% Newstop 39% Talentbottom 49% Globalbottom 37% Marketbottom 27% Funding: Raised $57.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $57M | 1 mo ago | Series B | 10 | Howard Chang Co-Founder | — | — | — |
| 28 | VitriVax Developer of thermostable vaccines 37Funding top 23%Moat top 37%Patents top 42%Innovation top 48% All 6 signals ▾Fundingtop 23% Moattop 37% Patentstop 42% Innovationtop 48% Marketbottom 36% Globalbottom 36% Funding: Raised $55.5M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 7 patents rank vs industry peers · Fliar Intelligence Index 37/100 | $56M | 7 mo ago | Series B | 24 | — | — | 7 patents Stable nucleic‑acid formulations and advanced chemical vapor deposition coating technologies | 1 job opening |
| 29 | BridGene Biosciences Developer of small-molecule drugs for the treatment of cancer 69Growth top 20%Patents top 23%Funding top 24%Innovation top 26% All 8 signals ▾Growthtop 20% Patentstop 23% Fundingtop 24% Innovationtop 26% Moattop 28% Talenttop 38% Globalbottom 40% Marketbottom 36% Growth: Headcount 15 → 25 (+67%) across vintages · Fresh capital in last 24 mo Patents: 44 patents matched (strict assignee match) · 35 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $50M | 8 mo ago | Series B | 25 25 → 31 (+24%) | Irene Yuan Co-Founder & Executive Vice President | — | 44 patents Small-molecule kinase and YAP/TAZ-TEAD inhibitors for targeted cancer therapy | — |
| 30 | Metaphore Provider of machine language and computational platform for drug discovery 42Funding top 23%Talent top 28%Moat top 42%AI top 45% All 7 signals ▾Fundingtop 23% Talenttop 28% Moattop 42% AItop 45% Globalbottom 36% Techbottom 35% Marketbottom 31% Funding: Raised $50.0M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $50M | 2 mo ago | Series C | 30 | Noubar Afeyan Co-Founder | — | — | — |
| 31 | Profluent Bio Provider of an artificial intelligence-based protein design platform 50Funding top 23%AI top 30%Talent top 33%Moat top 39% All 8 signals ▾Fundingtop 23% AItop 30% Talenttop 33% Moattop 39% Growthtop 45% Techbottom 45% Globalbottom 37% Marketbottom 28% Funding: Raised $44.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) AI: Classified as an AI company · Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 50/100 | $44M | 6 mo ago | Series B | 10 | Alexander Meeske Co-Founder | — | — | 1 partnership |
| 32 | Predictive Oncology AI-based cancer diagnostic and precision medicines platform 42Funding top 31%Tech top 41%AI top 45%Moat top 48% All 10 signals ▾Fundingtop 31% Techtop 41% AItop 45% Moattop 48% Fin. healthbottom 49% Talentbottom 49% Newsbottom 41% Growthbottom 40% Globalbottom 37% Marketbottom 33% Funding: Raised $43.0M across 9 rounds · 9 rounds over 18 yrs (0.5/yr) Tech: 51 technologies across 3/8 capability areas · Cloud: Akamai, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 42/100 | $43M | 8 mo ago | Acquired | 31 | Carl Schwartz CEO | 3 signals ▼62% Earnings | — | — |
| 33 | Unnatural Products Developer of computational biology techniques platform to engineer peptides for undruggable targets 27Funding top 25%Moat top 48%Global bottom 38%Market bottom 35% All 5 signals ▾Fundingtop 25% Moattop 48% Globalbottom 38% Marketbottom 35% Newsbottom 33% Funding: Raised $38.0M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Moat: Editorial + unicorn rating 5/10 · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 27/100 | $38M | 3 mo ago | Series B | 22 | — | — | — | — |
| 34 | Techcyte Artificial intelligence (AI) based image analysis platform for pathologists 72AI top 22%Funding top 30%Product top 30%Patents top 32% All 11 signals ▾AItop 22% Fundingtop 30% Producttop 30% Patentstop 32% Moattop 32% Innovationtop 33% Growthtop 35% Newstop 39% Techtop 48% Marketbottom 47% Globalbottom 40% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $35.4M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $35M | 1 mo ago | Series B | 100 | — | — | 34 patents Automated image analysis for microscopy and agglutination-based diagnostic assays. | 1 partnership |
| 35 | Quartzy Provider of web-based platform for labs management 67Funding top 24%Growth top 26%Tech top 37%Innovation top 38% All 10 signals ▾Fundingtop 24% Growthtop 26% Techtop 37% Innovationtop 38% Moattop 39% Producttop 42% Marketbottom 49% Talentbottom 49% Newsbottom 47% Globalbottom 37% Funding: Raised $33.9M across 6 rounds · 6 rounds over 14 yrs (0.4/yr) Growth: Headcount 54 → 97 (+80%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 67/100 | $34M | 2 mo ago | Series C | 97 97 → 92 (-5%) | Adam Regelman Co-Founder & CPO | — | — | 1 job opening · 1 launch · 2 partnerships |
| 36 | Atommap Provider of physics-based and ML-augmented computational drug discovery platform 65Funding top 28%Talent top 35%Global bottom 25% All 3 signals ▾Fundingtop 28% Talenttop 35% Globalbottom 25% Funding: Raised $31.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 3 named leaders on record rank vs industry peers · Fliar Intelligence Index 65/100 | $31M | 3 mo ago | Series C | — | Yujie Wu Co-Founder & CTO | — | — | — |
| 37 | Pi Health Provider of an AI-native platform for managing clinical trials end-to-end 62Patents top 20%Moat top 21%Growth top 28%Innovation top 31% All 11 signals ▾Patentstop 20% Moattop 21% Growthtop 28% Innovationtop 31% Fundingtop 31% Talenttop 38% AItop 45% Techbottom 47% Globalbottom 45% Marketbottom 29% Newsbottom 18% Patents: 9,865 patents matched (strict assignee match) · 2246 filings since 2022 vs 3287 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 9,865 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $31M | 4 mo ago | Series A | — | Bobby Reddy Md Co-Founder and COO | — | 9,865 patents Cell-based immunotherapies, engineered NK/CAR cells, and PET imaging agents for oncology | 1 job opening |
| 38 | Triomics Provider of clinical research and clinical trial tracking software 60AI top 20%Funding top 26%Talent top 38%Moat top 39% All 8 signals ▾AItop 20% Fundingtop 26% Talenttop 38% Moattop 39% Techtop 40% Growthtop 47% Globalbottom 43% Marketbottom 35% AI: Classified as an AI company Funding: Raised $28.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $29M | 0 mo ago | Series B | 29 | Hrituraj Singh Co-Founder & CTO | — | — | — |
| 39 | Arpeggio Provider of drug discovery platform for the treatment of cancer 24Funding top 27%Moat top 31%Talent top 38%Global bottom 37% All 6 signals ▾Fundingtop 27% Moattop 31% Talenttop 38% Globalbottom 37% Marketbottom 25% Newsbottom 22% Funding: Raised $25.4M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $25M | 7 mo ago | Series B | 8 | Laura Norris Co-Founder | — | — | — |
| 40 | Condor Software-based financial management platform for clinical industries 29Funding top 27%News top 29%Talent top 38%Tech top 45% All 9 signals ▾Fundingtop 27% Newstop 29% Talenttop 38% Techtop 45% Moattop 48% Innovationbottom 46% Productbottom 45% Globalbottom 32% Marketbottom 21% Funding: Raised $24.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 3 BI events in 12 mo (of 5 tracked, 3 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $24M | 3 mo ago | Series A | 8 | John Sammataro Co-Founder | 3 signals ▲200% Funding | — | — |
| 41 | Curi Bio Manufacturer of drugs for multiple therapautic areas 60Funding top 25%Growth top 28%Tech top 33%Talent bottom 49% All 8 signals ▾Fundingtop 25% Growthtop 28% Techtop 33% Talentbottom 49% Newsbottom 42% Marketbottom 40% Moatbottom 38% Globalbottom 37% Funding: Raised $21.0M across 13 rounds · 13 rounds over 5 yrs (2.6/yr) Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $21M | 6 mo ago | Series B | 47 47 → 57 (+21%) | Nicholas Geisse CEO | — | — | — |
| 42 | Sinopia Biosciences Data-driven drug discovery using multi-omics, AI, and disease models 13Funding top 28%AI top 45%Global bottom 29%Tech bottom 26% All 5 signals ▾Fundingtop 28% AItop 45% Globalbottom 29% Techbottom 26% Marketbottom 16% Funding: Raised $19.4M across 13 rounds · 13 rounds over 5 yrs (2.6/yr) AI: Product described with: machine learning rank vs industry peers · Fliar Intelligence Index 13/100 | $19M | 2 mo ago | Funding Raised | 4 | — | — | — | — |
| 43 | Ten63 Developer of therapeutics for undruggable targets 21Talent top 28%Funding top 32%Moat top 35%News top 44% All 7 signals ▾Talenttop 28% Fundingtop 32% Moattop 35% Newstop 44% Globalbottom 39% Techbottom 26% Marketbottom 24% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $18.3M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $18M | 3 mo ago | Series A | 10 | Mark Hallen Co-Founder & CTO | — | — | — |
| 44 | General Proximity Developer of next generation of induced-proximity medicines 22Funding top 31%Talent bottom 49%Global bottom 48%Tech bottom 42% All 5 signals ▾Fundingtop 31% Talentbottom 49% Globalbottom 48% Techbottom 42% Marketbottom 24% Funding: Raised $16.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 22/100 | $16M | 1 mo ago | Seed | 11 | Armand Cognetta III Founder & CEO | — | — | — |
| 45 | Dandelion Health Provider of AI-powered real-world data platform for clinical development 37Talent top 28%Funding top 34%Moat top 39%AI top 45% All 6 signals ▾Talenttop 28% Fundingtop 34% Moattop 39% AItop 45% Globalbottom 37% Marketbottom 24% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $15.9M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $16M | 1 mo ago | Series A | 7 | Elliott Green Co-Founder & CEO | — | — | 1 partnership |
| 46 | Genialis Developer of end-to-end bioinformatics software solutions 53Funding top 33%Growth top 35%Moat top 37%Patents top 38% All 10 signals ▾Fundingtop 33% Growthtop 35% Moattop 37% Patentstop 38% Innovationtop 39% Talenttop 41% Producttop 46% Techtop 50% Globalbottom 44% Marketbottom 35% Funding: Raised $15.3M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $15M | 6 mo ago | Series A | 35 | Rafael Rosengarten Chief Executive Officer | — | 17 patents Patents concentrated in computing, sensing & instrumentation | 1 launch |
| 47 | Blank Bio Developer of RNA foundation models for precision medicine research applications 60Talent top 28%Funding top 35%Global bottom 48% All 3 signals ▾Talenttop 28% Fundingtop 35% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $7.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $7M | 1 mo ago | Seed | — | Jonathan Hsu Co-Founder & CEO | — | — | — |
| 48 | Century Health AI-powered health tech company accelerating access to breakthrough treatments 45Funding top 35%Talent top 38%AI top 45%Market bottom 37% All 5 signals ▾Fundingtop 35% Talenttop 38% AItop 45% Marketbottom 37% Globalbottom 29% Funding: Raised $7.0M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $7M | 1 mo ago | Seed | — | Vish Srivastava Co-Founder & CEO | — | — | — |
| 49 | Pharma Solutions Provider of compliance automation software for pharmaceutical industries 45Moat top 28%Patents top 33%Growth top 35%Innovation top 41% All 9 signals ▾Moattop 28% Patentstop 33% Growthtop 35% Innovationtop 41% Fundingtop 42% Talentbottom 49% Techbottom 46% Globalbottom 35% Marketbottom 34% Moat: Editorial + unicorn rating 4/10 · IP moat: 248 patents Patents: 248 patents matched (strict assignee match) · 33 filings since 2022 vs 99 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $7M | 2 mo ago | Series A | 43 | Sumeet Singh Founder & CEO | — | 248 patents Oral zirconium silicate potassium binders for hyperkalemia treatment | — |
| 50 | NeoSoma Provider of an AI-based image analysis and decision-making platform for neurooncologist 40AI top 28%Funding top 40%Patents top 40%Moat top 42% All 8 signals ▾AItop 28% Fundingtop 40% Patentstop 40% Moattop 42% Innovationtop 48% Talentbottom 49% Globalbottom 35% Marketbottom 29% AI: Holds AI/ML patents (G06N-family CPC) · Product described with: ai-based Funding: Raised $6.3M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $6M | 3 mo ago | Series B | 13 | Ken Kolodziej Co-Founder & CEO | — | 7 patents AI-driven MRI segmentation and volumetric analysis of high-grade brain gliomas | — |
Top 12 Life Sciences Tech companies in United States
#1
Verily 🦄Series D · Dallas, Texas · founded 2015 · 1564 employees$2.5Braised▾
Verily 🦄
Series D · Dallas, Texas · founded 2015 · 1564 employees
A data platform and technology company purpose-built to power AI-enabled precision health. The company combine deep clinical, regulatory, and technological expertise to provide customers with patient-centric solutions that make healthcare more personal and precise. The solutions are designed to make healthcare data AI-ready and fit for purpose across care, research, and public health.
Fliar Intelligence Index™ 84how this company ranks against its industry peers
News
top 13%Funding
top 14%Talent
top 22%Growth
top 25%Moat
top 26%Tech
top 30%News: 7 BI events in 12 mo (of 67 tracked, 9 types) · +600% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding: Raised $2.5B across 5 rounds · 5 rounds over 9 yrs (0.6/yr) · Last round Series D (Mar 2026)
Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 181k LinkedIn followers — 19.3% of this cohort's audience
Funding rounds
- Mar 2026Series D$300M
- Apr 2025Grant (prize money)$14.7M
- Sep 2022PE—
- Dec 2020PE$700M
Founders & team
Investors
Silver Lake, Ontario Teachers' Pension Plan, Temasek, Swiss Re, The Michael J. Fox Foundation, Series X Capital
Tech stack
Apple Icloud MailCore-JsDocusignEmotionGoogle AnalyticsGoogle Cloud
#2
Series D · Middletown, Delaware · founded 2021$787Mraised▾
Series D · Middletown, Delaware · founded 2021
Provider of AI-driven technology platforms that enable the discovery and development of protein therapeutics. It transform the discovery of protein therapeutics using deep learning and high-throughput biology. The company aims to deliver transformative medicines to patients worldwide through its innovative approaches.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 12%AI
top 35%Talent
top 38%Patents
top 46%Innovation
top 50%Global
top 50%Funding: Raised $787M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series D (Mar 2026)
AI: Product described with: ai-driven, deep learning
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding rounds
- Mar 2026Series D$787M
Founders & team
Investors
Dimension, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi Ventures
#3
Series C · San Diego, California · founded 2019 · 50 employees$206.2Mraised▾
Series C · San Diego, California · founded 2019 · 50 employees
Provider of AI-driven drug discovery platform for the treatment of cancer. It offers an AI driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1 a potential first-in-class selective dual CDK2/4 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell cycle driven cancers.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 15%AI
top 26%Moat
top 31%Talent
top 38%Growth
top 45%Market
bottom 43%Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Series C (Apr 2026)
AI: Classified as an AI company · Product described with: ai driven, ai-driven
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Apr 2026Series C$27.8M
- Nov 2025Series C$100M
- Apr 2024Series B$50M
- Oct 2023Series B$103.2M
Founders & team
Investors
Ascenta Capital, Abingworth, Nvidia, Illumina Ventures, Shanda, Catalio Capital Management
Tech stack
Apple Icloud MailCloudflareDocusignGoogle Font ApiGoogle Hosted LibrariesHsts
#4
Series B · Cambridge, Massachusetts · founded 2008 · 60 employees$140Mraised▾
Series B · Cambridge, Massachusetts · founded 2008 · 60 employees
AI-based cancer detection tool for providers. The company has developed a blood test detection tool that enables professionals to analyze and detect early cancers.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 18%News
top 36%Moat
top 42%AI
top 45%Talent
top 49%Tech
bottom 48%Funding: Raised $140M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Apr 2026)
News: 2 BI events in 12 mo (of 13 tracked, 3 types) · Top themes: Leadership
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 8k LinkedIn followers
Activity (LinkedIn): 2 product launches announced in 12 mo
Funding rounds
- Apr 2026Series B$100M
- Sep 2023Series B$140M
- 2021Series A$50M
Founders & team
Investors
Flagship Pioneering, Pictet Group, Partners Investment, Venture Catalysts, M&G, Camillus LifeSciences
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCore-JsGoogle AnalyticsGoogle Font Api
#5
XtalPi 🦄Public · Cambridge, Massachusetts · founded 2014 · 27 employees$784.8Mraised▾
XtalPi 🦄
Public · Cambridge, Massachusetts · founded 2014 · 27 employees
XtalPi has developed a proprietary technology FACES(Fast Accurate Crystalline Engineering System), which is a cloud-based computing system to predict the crystal structure which will identify polymorphs of the compound. The company's algorithms are integrated with the Amazon Web Service (AWS) high-performance computing (HPC) resources in the cloud. The team claims to have a strong background in quantum physics and machine learning. It provides services to pharmaceutical companies at various stages of drug development. The company has deployed its technology to develop an Intelligent Digital Drug Discovery and Development (ID4) platform to improve the efficiency, accuracy, and success rate of drug discovery.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 18%AI
top 26%Talent
top 28%Patents
top 31%Moat
top 31%Innovation
top 34%Funding: Raised $785M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) · Last round Post IPO (Sep 2025)
AI: Classified as an AI company · Product described with: ai-based, machine learning
Talent: Analyst team rating 4/5
Audience (LinkedIn): 18k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. OpenEye, Cadence Molecular Sciences) announced in 12 mo
Funding rounds
- Sep 2025Post IPO$268M
- Feb 2025Post IPO$268.4M
- Aug 2021Series D$400M
- Sep 2020Series C$318.8M
Investors
Tencent, Frees Fund, Zhen Fund, Renren, SoftBank Vision Fund, People's Insurance Company of China
Tech stack
Animate.CssBootstrapCdnjsCloudflareCloudflare Bot ManagementCore-Js
#6
Series C · Boston, Massachusetts · founded 2018 · 48 employees$83Mraised▾
Series C · Boston, Massachusetts · founded 2018 · 48 employees
Platform offering CRM software to the medical industry. The platform enables members to personalize customer engagement, identify and quantify opportunities, forecast sales accurately, understand the value of the sales pipeline, empower the sales team, track new launches, understand product adoption and market penetration.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 18%News
top 25%Talent
top 28%Growth
top 35%Product
top 36%Moat
top 39%Funding: Raised $83.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series C (Apr 2026)
News: 4 BI events in 12 mo (of 11 tracked, 3 types) · Top themes: Funding, New product
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 15k LinkedIn followers
Funding rounds
- Apr 2026Series C$80M
- Jun 2024Series B$45M
- May 2022Series A$31M
- May 2021Series A$7M
Founders & team
Investors
Iconiq Capital, Atreides Management, StepStone Group, Redpoint Ventures, Benchmark, Artisanal Ventures
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-JsFacebook Pixel
#7
Series A · Cambridge, Massachusetts · founded 2021 · 2 employees$109.5Mraised▾
Series A · Cambridge, Massachusetts · founded 2021 · 2 employees
Provider of a platform that utilizes epitope-level resolution to unlock cellular profiling and target discovery. The platform technology enables single-cell profiling and target identification for ddrug discovery and development of cancer immunotherapy and others.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 20%Talent
top 38%Global
bottom 48%Tech
bottom 25%Market
bottom 19%Funding: Raised $109M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Mar 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Global: Investors from 1 country beyond United States
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Lonza) announced in 12 mo
Funding rounds
- Mar 2026Series A$100M
- Dec 2024Series A$9.5M
Founders & team
Investors
RA Capital Management, Andreessen Horowitz, Nextech Invest, Emerson Collective, Google Ventures, GordonMD Global Investments
Tech stack
AstraCore-JsElementorGoogle Font ApiGoogle Hosted LibrariesJquery
#8
Series C · San Jose, California · founded 2017 · 165 employees$166.1Mraised▾
Series C · San Jose, California · founded 2017 · 165 employees
BrightInsight provides digital health solutions for clinical trials. Their platform enables improving patient engagement and adherence, continuous remote patient monitoring, and dose management algorithms (cloud-based algorithm). It analyzes data from connected medical devices, combination products, apps, and software. The company's Quality Management System is ISO 13485: 2016 certified.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 18%Moat
top 31%Growth
top 35%Market
top 50%Tech
bottom 49%Talent
bottom 49%Funding: Raised $166M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series C (Jan 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 21k LinkedIn followers — 2.2% of this cohort's audience
Activity (LinkedIn): 2 partnerships (incl. Havas Health Network) announced in 12 mo
Funding rounds
- Jan 2026Series C$13M
- Mar 2021Series C$101M
- Jun 2020Series B$40.1M
- Sep 2019Series A$25M
Founders & team
Investors
General Catalyst, Insight Partners, New Leaf Venture Partners, Eclipse, Mayo Clinic, PROOF
Tech stack
6SenseCloudflareCloudflare Bot ManagementCore-JsDocusignFullstory
#9
Series B · Cambridge, Massachusetts · founded 2021 · 33 employees$100Mraised▾
Series B · Cambridge, Massachusetts · founded 2021 · 33 employees
Developer of allosteric therapeutics for precision oncology and rare diseases. The company integrated with proprietary drug discovery platform that enables to unlock novel allosteric binding pockets and rapidly advance structural insights into small molecule therapeutics designt to unlock cryptic allosteric sites across a broad range of target classes.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 19%Talent
top 28%Moat
top 31%Market
bottom 42%Global
bottom 36%News
bottom 33%Funding: Raised $100M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series B (Mar 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Mar 2026Series B$40M
- Dec 2025Series B$120M
- Dec 2023Series A$40M
- Aug 2021Series A$60M
Founders & team
Investors
The Column Group, Lux Capital, Nextech Invest, Regeneron Ventures, RA Capital Management
#10
Series B · Foster City, California · founded 2020 · 10 employees$57Mraised▾
Series B · Foster City, California · founded 2020 · 10 employees
Provider of a platform to discover immunotherapeutics. It provides a platform that combines computational and experimental techniques to profile antigens of cancerous cells and identify targets for immuno-oncology treatments.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 23%Moat
top 31%News
top 39%Talent
bottom 49%Global
bottom 37%Market
bottom 27%Funding: Raised $57.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
News: 2 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding, Leadership
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- May 2026Series B—
- Oct 2025Series B$67M
- Jul 2022Series A$57M
Founders & team
Investors
8VC, Dren Bio, Hexagon, Myeloid Therapeutics, Alloy Therapeutics, Andreessen Horowitz
#11
Series B · Boston, Massachusetts · founded 2014 · 30 employees$99.2Mraised▾
Series B · Boston, Massachusetts · founded 2014 · 30 employees
Provider of a cloud-based data platform for life science industry. It provides a platform that automatically gathers scientific data from lab equipment, gets data ready for analysis and display, and re-engineers raw or primary data into harmonised data.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 21%Growth
top 26%Moat
top 35%Tech
top 50%News
bottom 47%Global
bottom 39%Funding: Raised $99.2M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) · Last round Series B (Feb 2026)
Growth: Headcount 13 → 30 (+131%) across vintages · Web rank 5,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 8/10 · IP moat: 4 patents · Soonicorn
Audience (LinkedIn): 57k LinkedIn followers — 6.1% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Senior Product Manager
Funding rounds
- Feb 2026Series B$15M
- Apr 2021Series B$80M
- 2020Series A$11M
- Oct 2019Series A$8M
Investors
Underscore VC, Impetus VC, Alkeon Capital Management, Insight Partners, Y Combinator, Founder Collective
Tech stack
6SenseAmazon SesAmazon Web ServicesApple Icloud MailCloudflareCloudflare Bot Management
#12
Enveda 🦄Series D · Boulder, Colorado · founded 2019$504.8Mraised▾
Enveda 🦄
Series D · Boulder, Colorado · founded 2019
AI-based platform to decipher the chemistry of nature and develop new medicines. It employs advanced computational methods, high throughput automation, and metabolomics to identify potential treatments for various diseases. It leverages chemical knowledge of nature to accelerate drug discovery and development.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 12%Moat
top 32%Growth
top 35%Market
top 44%AI
top 45%Talent
bottom 49%Funding: Raised $505M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) · Last round Series D (Sep 2025)
Moat: Unicorn · 10 curated direct competitors tracked
Growth: Fresh capital in last 24 mo
Funding rounds
- Sep 2025Series D$150M
- Feb 2025Series C—
- Nov 2024Series C$130M
- Jun 2024Series B$55M
Founders & team
Investors
SVB, FPV Ventures, JAZZ Venture Partners, Level Ventures, Amino Collective, Allen & Company
Tech stack
Apple Icloud MailBootstrapCloudflareCloudflare Bot ManagementCore-JsCrazy Egg
Funding & investor landscape
$41.1Btotal disclosed funding
882companies funded
2,669disclosed rounds
20rounds last 90 days
Most active investors
Notable founders
Andrew Conrad
Co-Founder · Verily
Jessica Mega
Co-Founder · Verily
Zhenping Zhu
Co-Founder & Co-CEO · Earendil
Jian Peng
Founder & Co-CEO · Earendil
Fred Manby
Co-Founder & CTO · Iambic Therapeutics
Thomas Miller
Co-Founder & CEO · Iambic Therapeutics
Stephen Hahn
CEO · Harbinger Health
Michael Monovoukas
Co-Founder & CEO · AcuityMD
Robert Coe
Co-Founder & CTO · AcuityMD
Aaron Ring
Co-Founder · Stipple Bio
Aashish Manglik
Co-Founder · Stipple Bio
Frederik Smits
Co-founder & Managing Director · BrightInsight
Prism market signals · United States · country-scoped Prism corpus, 2,593,976 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Tech coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research is surging — papers rose from 33 to 164, leading all sub-topics.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements are intensifying — both jumped from ~3 to 62 papers.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern research is rising sharply — papers tripled from 15 to 45 across U.S. institutions.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18113
- UNIV California17975
- Regeneron Pharma16083
- Amgen10515
- Monsanto Technology9755
- UNIV Pennsylvania8528
- Harvard College7464
- UNIV Texas7384
Common questions
How many Life Sciences Tech companies are there in United States?
Radar tracks 2222 indexable Life Sciences Tech companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences Tech companies in United States?
The Life Sciences Tech companies in United States on this list have raised a combined $41.1B in disclosed equity funding across 882 funded companies.
Which is the highest-funded Life Sciences Tech company in United States?
Verily is the highest-funded Life Sciences Tech company in United States, with $2.5B in disclosed equity funding.
How many Life Sciences Tech companies in United States are funded?
882 of the 2222 Life Sciences Tech companies in United States on this list have disclosed at least one equity funding round.
How many Life Sciences Tech unicorns are there in United States?
23 Life Sciences Tech companies in United States on this list are valued at $1B or more.
Who are the top investors in United States Life Sciences Tech companies?
The most active investors in United States Life Sciences Tech companies on this list include HHS, Y Combinator, National Science Foundation, NIH, Lux Capital.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.